RMSF: Clinical Presentation

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 148 CE courses, most popular
$95Add to cart
Pick Your Courses
Up to 8 CE hours
$50Add to cart
Individual course$20Add to cart
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Tickborne Diseases. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Tickborne Diseases (online CE course)
RMSF: Clinical Presentation

The incubation period for RMSF is about seven days, with a range of 2 to 14 days after the tick bite. Patients usually present with an abrupt onset of severe headache, fever, chills, weakness, and myalgias. Later, a nonproductive cough may develop. Gastrointestinal manifestations are very common (eg, nausea, vomiting, loss of appetite). Meningitis and meningoencephalitis may seldom occur.
The rash appears two to four days after the onset of symptoms. Most patients seek care before the rash develops, so a strong suspicion of RMSF is required. Treatment with doxycycline should be started before a definitive diagnosis is made. The rash begins as small, blanching macules on the wrists, ankles, or forearms. It evolves to maculopapules and spreads to the entire body, including the palms and soles. 50% of rashes become petechial and hemorrhagic, which is associated with more severe disease. 20% of rashes may be atypical. Nonspecific laboratory findings include:
  • Normal WBC count with a left shift
  • Decreased platelets
  • Slightly elevated transaminases and other liver enzymes
  • CSF examination may demonstrate neutrophils or lymphocytes, an elevated protein, and normal glucose
  • Hyponatremia
75% of infected patients are hospitalized and have peak temperatures greater than 104° F (40° C) and almost 50% have peak temperatures greater than 40.5° C. 25% develop delirium, ataxia, stupor, or coma. Death is uncommon, but when it occurs, it is 1-2 weeks after the onset of symptoms and in the 4-8% of cases not treated with an effective antimicrobial, such as doxycycline.